El CRAI romandrà tancat del 24 de desembre de 2025 al 6 de gener de 2026. La validació de documents es reprendrà a partir del 7 de gener de 2026.
El CRAI permanecerá cerrado del 24 de diciembre de 2025 al 6 de enero de 2026. La validación de documentos se reanudará a partir del 7 de enero de 2026.
From 2025-12-24 to 2026-01-06, the CRAI remain closed and the documents will be validated from 2026-01-07.
 
Miniatura

Fitxers

709026.pdf (747.2 KB)

Tipus de document

Article

Versió

Versió publicada

Data de publicació

2020-10-13

Llicència de publicació

cc-by (c) Amat Bou, Montse et al., 2020
Si us plau utilitzeu sempre aquest identificador per citar o enllaçar aquest document: https://hdl.handle.net/2445/176194

Effects of Bifidobacterium animalis Subsp. lactis (BPL1) Supplementation in Children and Adolescents with Prader-Willi Syndrome: A Randomized Crossover Trial

Títol de la revista

Autors

Director/Tutor

ISSN de la revista

Títol del volum

Recurs relacionat

https://doi.org/10.3390/nu12103123

Resum

Prader-Willi syndrome (PWS) is a rare genetic disorder characterized by a wide range of clinical manifestations, including obesity, hyperphagia, and behavioral problems. Bifidobacterium animalis subsp. lactis strain BPL1 has been shown to improve central adiposity in adults with simple obesity. To evaluate BPL1's effects in children with PWS, we performed a randomized crossover trial among 39 patients (mean age 10.4 years). Participants were randomized to placebo-BPL1 (n = 19) or BPL1-placebo (n = 20) sequences and underwent a 12-week period with placebo/BPL1 treatments, a 12-week washout period, and a 12-week period with the crossover treatment. Thirty-five subjects completed the study. The main outcome was changes in adiposity, measured by dual-energy X-ray absorptiometry. Secondary outcomes included lipid and glucose metabolism, hyperphagia, and mental health symptoms. Generalized linear modeling was applied to assess differences between treatments. While BPL1 did not modify total fat mass compared to placebo, BPL1 decreased abdominal adiposity in a subgroup of patients older than 4.5 years (n = 28). BPL1 improved fasting insulin concentration and insulin sensitivity. Furthermore, we observed modest improvements in some mental health symptoms. A follow-up trial with a longer treatment period is warranted to determine whether BPL1 supplementation can provide a long-term therapeutic approach for children with PWS (ClinicalTrials.gov NCT03548480).

Matèries

Síndrome de Prader-Willi, Bulímia, Microbiota intestinal

Matèries (anglès)

Prader-Willi syndrome, Bulimia, Gastrointestinal microbiome

Citació

Col·leccions

Articles publicats en revistes (Cirurgia i Especialitats Medicoquirúrgiques)

Citació

AMAT BOU, Montse, GARCÍA RIBERA, Sonika, CLIMENT, Eric, PIQUER GARCÍA, Irene, CORRIPIO, Raquel, SÁNCHEZ INFANTES, David, VILLALTA, Laia, ELIAS, María, JIMÉNEZ CHILLARÓN, Josep c., CHENOLL, Empar, RAMÓN, Daniel, IBÁÑEZ TODA, Lourdes, RAMÓN KRAUEL, Marta, LERIN, Carles. Effects of Bifidobacterium animalis Subsp. lactis (BPL1) Supplementation in Children and Adolescents with Prader-Willi Syndrome: A Randomized Crossover Trial. _Nutrients_. 2020. Vol. 12, núm. 10, pàgs. 3123. [consulta: 7 de gener de 2026]. ISSN: 2072-6643. [Disponible a: https://hdl.handle.net/2445/176194]

Exportar metadades

JSON - METS

Compartir registre